DK0807124T3 - Monoklonalt antistof mod FLT4-receptor-tyrosinkinase og anvendelse heraf i diagnose og terapi - Google Patents

Monoklonalt antistof mod FLT4-receptor-tyrosinkinase og anvendelse heraf i diagnose og terapi

Info

Publication number
DK0807124T3
DK0807124T3 DK95922533T DK95922533T DK0807124T3 DK 0807124 T3 DK0807124 T3 DK 0807124T3 DK 95922533 T DK95922533 T DK 95922533T DK 95922533 T DK95922533 T DK 95922533T DK 0807124 T3 DK0807124 T3 DK 0807124T3
Authority
DK
Denmark
Prior art keywords
diagnosis
therapy
monoclonal antibody
tyrosine kinase
antibody against
Prior art date
Application number
DK95922533T
Other languages
Danish (da)
English (en)
Inventor
Kari Alitalo
Paeivi Karnani
Arja Kaipainen
Jaana Korhonen
Tuija Mustonen
Katri Pajusola
Marja-Terttu Matikainen
Original Assignee
Licentia Oy
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Licentia Oy, Ludwig Inst Cancer Res filed Critical Licentia Oy
Application granted granted Critical
Publication of DK0807124T3 publication Critical patent/DK0807124T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK95922533T 1994-06-09 1995-06-09 Monoklonalt antistof mod FLT4-receptor-tyrosinkinase og anvendelse heraf i diagnose og terapi DK0807124T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25775494A 1994-06-09 1994-06-09

Publications (1)

Publication Number Publication Date
DK0807124T3 true DK0807124T3 (da) 2006-08-28

Family

ID=22977612

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95922533T DK0807124T3 (da) 1994-06-09 1995-06-09 Monoklonalt antistof mod FLT4-receptor-tyrosinkinase og anvendelse heraf i diagnose og terapi

Country Status (14)

Country Link
EP (1) EP0807124B1 (fr)
JP (4) JP3723210B2 (fr)
AT (1) ATE326484T1 (fr)
AU (1) AU694524B2 (fr)
CA (1) CA2192235C (fr)
DE (1) DE69534996T2 (fr)
DK (1) DK0807124T3 (fr)
ES (1) ES2263152T3 (fr)
FI (1) FI964862L (fr)
MX (1) MX9606218A (fr)
NO (1) NO319383B1 (fr)
NZ (1) NZ288235A (fr)
PT (1) PT807124E (fr)
WO (1) WO1995033772A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6130071A (en) * 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6221839B1 (en) 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
EP1353952B1 (fr) 1994-11-14 2007-04-11 Ludwig Institute For Cancer Research Flt4 (vegfr-3) utilise comme cible pour l'imagerie des tumeurs et le traitement antitumoral
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
ATE242809T1 (de) 1995-09-08 2003-06-15 Genentech Inc Vegf-verwandtes protein
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
FR2783325A1 (fr) * 1998-09-11 2000-03-17 Inst Nat Sante Rech Med Moyens pour le controle de la regulation negative d'une activation transmise par un rtk
NZ529063A (en) 1998-10-09 2005-07-29 Ludwig Inst Cancer Res Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
AU775583B2 (en) * 1999-04-13 2004-08-05 Medarex, Inc. Methods for the diagnosis and treatment of metastatic prostate tumors
EP1553414A1 (fr) * 1999-04-13 2005-07-13 Medarex, Inc. Procedes pour le diagnostic et le traitement de tumeurs metastatiques de la prostate
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US6599717B1 (en) * 1999-10-01 2003-07-29 Exelixis, Inc. Invertebrate vascular endothelial growth factor receptor
EP2025686A4 (fr) * 2006-05-29 2009-12-23 Consejo Superior Investigacion Anticorps monoclonaux anti-choline kinase alpha et leur application dans des techniques d'analyse, de diagnostic du cancer et dans la préparation de médicaments
EP2125895B1 (fr) 2007-02-02 2015-04-08 Vegenics Pty Ltd Antagoniste du recepteur de facteurs de croissance pour l'allo-immunite de greffe d'organe et l'arteriosclerose
MX368730B (es) 2013-02-18 2019-10-14 Vegenics Pty Ltd Moleculas que unen ligando y usos de las mismas.
EP2994758B1 (fr) 2013-05-08 2017-12-20 Opthea Limited Marqueurs biologiques de la dégénérescence maculaire liée à l'âge (dmla)
CN114262683B (zh) * 2022-03-01 2022-06-17 中国科学院动物研究所 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR940703857A (ko) * 1992-01-09 1994-12-12 티모 에스코 타이, 새로운 내피 세포 수용체 티로신 키나제(tie, a novel endothelial cell receptor tyrosine kinase)
CZ291047B6 (cs) * 1992-10-28 2002-12-11 Genentech, Inc. Farmaceutický prostředek obsahující antagonisty faktoru růstu vaskulárních endoteliálních buněk

Also Published As

Publication number Publication date
CA2192235A1 (fr) 1995-12-14
NZ288235A (en) 1999-05-28
DE69534996D1 (de) 2006-06-22
FI964862A7 (fi) 1997-02-10
AU694524B2 (en) 1998-07-23
JP2009102415A (ja) 2009-05-14
JP3723210B2 (ja) 2005-12-07
MX9606218A (es) 1998-02-28
JP2005139199A (ja) 2005-06-02
EP0807124A1 (fr) 1997-11-19
NO965231D0 (no) 1996-12-06
CA2192235C (fr) 2011-02-15
FI964862A0 (fi) 1996-12-04
AU2738895A (en) 1996-01-04
NO319383B1 (no) 2005-07-25
DE69534996T2 (de) 2007-05-10
ATE326484T1 (de) 2006-06-15
PT807124E (pt) 2006-08-31
EP0807124B1 (fr) 2006-05-17
ES2263152T3 (es) 2006-12-01
JPH10500858A (ja) 1998-01-27
FI964862L (fi) 1997-02-10
WO1995033772A1 (fr) 1995-12-14
JP2012193191A (ja) 2012-10-11
NO965231L (no) 1996-12-06

Similar Documents

Publication Publication Date Title
DK0807124T3 (da) Monoklonalt antistof mod FLT4-receptor-tyrosinkinase og anvendelse heraf i diagnose og terapi
DK0540573T3 (da) Assay for frit- og kompleksbundet prostataspecifikt antigen (PSA)
EP0914155A4 (fr) Anticorps monoclonaux de l'antigene membranaire specifique de la prostate
CA2214488A1 (fr) Dosage du cpsa
DK1064303T3 (da) Monoklonale antistoffer, der er specifikke for det prostataspecifikke membranantigens ekstracellulære domæne
SE9600949D0 (sv) Method of diagnosing a mycobacterial disease and immunoassay kit
CA2361000A1 (fr) Inhibiteur de trypsine urinaire permettant de depister le sida
DE3780480D1 (de) Test fuer menschlichen brustkrebs.
NO177463C (no) STLV-III-beslektede polypeptider, diagnostiske prövesett og in vitro analysefremgangsmåte for påvisning av anti-HIV-2-antistoffer i kroppsvæskepröve
DE69839876D1 (de) Prostat-spezifisches-antigenformen und verfahren zu ihrer bestimmung
FR2795823B1 (fr) Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
ATE433575T1 (de) Neurotransmission-störungen
FI943921A0 (fi) Bestaemning av fri och komplexbunden trypsinogen-2
ES2019573T3 (es) Inmunoensayo para la deteccion de alfa-haloacetamidas.
ES2189254T3 (es) Dosificado inmunologico que permite detectar los anticuerpos igm especificos del citomegalovirus humano.
ES2075803A1 (es) Procedimiento de la deteccion de neumolisina
WO1990008956A1 (fr) Detection d'activateur de facteur tissulaire humain
IT1309442B1 (it) Procedimento di rivelazione immunoenzimatica di un complesso antigene/anticorpo primario e kit diagnostico per la sua attuazione.